Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nuwellis ( (NUWE) ) has shared an update.
On September 18, 2025, Nuwellis, Inc. announced the issuance of a new U.S. patent related to hemolysis sensors in blood filtration systems, which supports their pediatric device, Vivian, and future innovations. This patent issuance strengthens Nuwellis’ intellectual property portfolio, potentially enhancing their market position and innovation capabilities in the medical device sector.
The most recent analyst rating on (NUWE) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Spark’s Take on NUWE Stock
According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.
Nuwellis’ overall stock score is primarily impacted by its financial challenges, including ongoing losses and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. While recent corporate events and strategic initiatives offer some promise, the immediate financial outlook remains concerning.
To see Spark’s full report on NUWE stock, click here.
More about Nuwellis
Nuwellis, Inc. operates in the medical device industry, focusing on extracorporeal blood filtration systems, such as ultrafiltration therapy and continuous renal replacement therapy (CRRT), with a market focus on pediatric devices.
Average Trading Volume: 894,153
Technical Sentiment Signal: Sell
Current Market Cap: $3.58M
See more insights into NUWE stock on TipRanks’ Stock Analysis page.